Mesothelin-Guided CD40 Multispecific Antibodies for Reduced Toxicity
Solution Overview
Problem
Existing CD40 agonistic antibodies for treating solid tumors face challenges with systemic toxicities and limited efficacy due to immune-related adverse effects, such as cytokine release syndrome and liver damage, which restrict the dose and impact the activation of the CD40 pathway in tumor-associated APCs.
Innovation Solution
A multispecific antibody construct is engineered to specifically target CD40 on tumor-associated APCs by binding to mesothelin (MSLN), with mutations to limit Fc receptor binding, ensuring localized activation and reducing systemic toxicities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal anti-CD40 antibodies are used to activate CD40 signaling, then anti-tumor effects are enhanced, but systemic toxicities such as cytokine release syndrome and liver damage occur
Solution Approach 1:
The patent applies local quality by engineering the antibody to have different functional properties in different locations: the multispecific antibody construct is designed to activate CD40 signaling specifically in tumor tissue where both CD40 and mesothelin are present, while minimizing activation in non-tumor tissues. This spatial differentiation of antibody function resolves the contradiction between achieving systemic anti-tumor effects and avoiding systemic toxicities.
Solution Approach 2:
The patent uses mesothelin as an intermediary target to mediate selective CD40 activation. By requiring simultaneous binding to both mesothelin and CD40 for full activation, the antibody uses mesothelin as a mediator to restrict CD40 signaling primarily to tumor cells that express mesothelin, thereby enhancing anti-tumor efficacy while reducing off-target toxicities.
2Reliability
If CD40 agonist antibodies are administered at higher doses to improve efficacy, then tumor activation is enhanced, but immune-related adverse effects increase
Solution Approach 1:
The antibody construct achieves localized CD40 activation in tumor microenvironments through dual-specific binding, allowing effective tumor targeting without requiring high systemic doses that would cause immune-related adverse effects.
Solution Approach 2:
The patent changes the activation parameters of CD40 signaling by requiring bivalent engagement (both CD40 and mesothelin binding) for optimal activation. This parameter change creates a threshold effect where only tumor cells expressing both targets receive strong activation signals, reducing the need for high doses and minimizing adverse effects.
3Productivity
If conventional anti-CD40 antibodies are used, then broad immune activation occurs, but tumor localization is insufficient
Solution Approach 1:
The patent applies universality by creating a multispecific antibody that performs multiple functions: it binds to CD40 to activate immune cells, binds to mesothelin for tumor targeting, and utilizes Fc region interactions for immune cell recruitment. This multi-functionality enables both broad immune activation and precise tumor localization simultaneously.
Solution Approach 2:
The patent merges two separate antibody specificities (anti-CD40 and anti-mesothelin) into a single multispecific construct, combining tumor targeting capability with immune activation function in one molecule, thereby achieving both broad immune activation and precise tumor localization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multispecific antibody construct achieves robust CD40-mediated activation primarily in tumor tissue, enhancing anti-tumor effects while minimizing systemic toxicities, thus improving treatment outcomes for solid tumors.
Implementation Method 1
a multispecific antibody construct that binds both CD40 and a tumor-associated antigen, mesothelin
Implementation Method 2
Interaction with its trimeric ligand on activated T helper cells results in APC activation that includes upregulation of cytokines/chemokines
Data Source
AI summary
The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.